卡铂联合力尔凡治疗恶性胸腔积液临床研究

CLINICAL STUDY ON THE EFFECTS OF CARBOPLATINCOMBINED WITH LIFEIN IN MALIGNANT PLEURAL EFFUSION

目的 :评价卡铂和力尔凡联合用药治疗恶性胸腔积液的疗效和毒性。方法 :6 0例恶性胸腔积液患者随机分为两组 ,A组单用卡铂 ,B组卡铂与力尔凡联合应用。结果 :在治疗的第一个月 ,A组 CR率为81% ,B组 CR率为 88% ;3个月后 A组 CR率为 6 5 % ,B组 CR率为 99% ,两组差异均无显著性 (P>0 .0 5 ) ;6个月后 CR率 ,A组为 4 0 % ,B组为 6 0 % ,两组差异有显著性 (P<0 .0 5 ) ;6个月生存率两组均为 10 0 % (P>0 .0 5 ) ;12个月后 CR率 A组为 15 % ,B组为 35 .6 % (P<0 .0 5 ) ;18个月生存率 A组为0 ,B组为 16 .4 % (P<0 .0 5 )。两组不良反应主要有低热、胸痛、胃肠道反应 ,经对症处理可缓解。结论 :卡铂联合力尔凡治疗恶性胸腔积液的疗效明显高于卡铂单独用药。

Objective:To evaluate the effects and toxicities of carboplatin combined with lifein in malignant pleural effusion . Methods: sixty patients With malignant pleural effusion were randomly divided into 2 groups : In group A, only corboplatin was administered; In group B, Lifein ond Carboplatin were combined together to be administered. Results: In the first month , the CR rate was 81% in group and 88% in group B; After 3 moths,the CR rate was 65% in group A and 99% in group B (P>0.05); After 6 months, the CR rate was 40% in group A and 60% in group B (P<0.05); The6-month survival rate was 100% in 2 groups (P>0.05). After 12 months the CR rate was 15% in group A and 35.6% in group B (P<0.05); The 18-month survival rate was 0% in group A, 16.4% in group B .The main side effects were gastroentevic tract reacfion, thoracodynin and low fever which could be controlled. Conclusions: The curative effects of carboplatin combined with Lifein in the treatment of malignant pleural effusion is obviously superior to single carboplafin.